ARTA
LXRX icon

A.R.T. Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

A.R.T. Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20,677
Closed -$41K – 185
2020
Q2 		$41K Buy
+20,677
New +$40.5K 0.06% 233
2019
Q2 		– Sell
-48,152
Closed -$268K – 1513
2019
Q1 		$268K Buy
+48,152
New +$293K 0.02% 980
2018
Q4 		– Sell
-28,200
Closed -$300K – 1518
2018
Q3 		$300K Sell
28,200
-14,600
-34% -$167K 0.01% 1037
2018
Q2 		$513K Sell
42,800
-11,466
-21% -$117K 0.02% 910
2018
Q1 		$465K Buy
54,266
+22,533
+71% +$208K 0.02% 987
2017
Q4 		$313K Buy
+31,733
New +$330K 0.01% 1046
2017
Q3 		– Sell
-34,400
Closed -$565K – 1521
2017
Q2 		$565K Buy
34,400
+9,700
+39% +$150K 0.03% 749
2017
Q1 		$354K Sell
24,700
-9,700
-28% -$144K 0.02% 936
2016
Q4 		$475K Buy
+34,400
New +$552K 0.03% 772
2016
Q2 		– Sell
-14,574
Closed -$174K – 1511
2016
Q1 		$174K Buy
+14,574
New +$153K 0.01% 1200
2014
Q2 		– Sell
-18,519
Closed -$224K – 1432
2014
Q1 		$224K Sell
18,519
-57
-0.3% -$728 0.01% 1115
2013
Q4 		$234K Buy
18,576
+2,367
+15% +$37.7K 0.01% 1059
2013
Q3 		$270K Hold
16,209
– – 0.01% 1018
2013
Q2 		$246K Buy
+16,209
New +$246K 0.01% 1104

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

A.R.T. Advisors's LXRX Position: Q3 2020 in Review

A.R.T. Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2020, closing a stake of 20,677 shares — an estimated $41K sold.

A.R.T. Advisors first reported a position in LXRX in Q2 2013 and held it in 14 quarters. The position peaked at $565K in Q2 2017. 91 funds tracked by Wall St. Rank hold LXRX as of Q3 2020.

  • A.R.T. Advisors reported no remaining Lexicon Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 20,677 Lexicon Pharmaceuticals shares in Q3 2020, an estimated $41K.
  • A.R.T. Advisors first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • A.R.T. Advisors's Lexicon Pharmaceuticals position peaked at $565K in Q2 2017.
  • 91 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2020.

Based on A.R.T. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.